Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (621-630 of 738) with videos related to

Pageof 74
Sort By:
Kidney International|December 23, 2011
Renal outcomes in hypertensive Black patients at high cardiovascular riskMatthew R Weir, George L Bakris, Michael A Weber, et al.
The New England Journal of Medicine|September 3, 2013
Alogliptin after acute coronary syndrome in patients with type 2 diabetesWilliam B White, Christopher P Cannon, Simon R Heller, et al.
American Journal of Nephrology|November 13, 2009
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal diseaseVibha Bhatnagar, Erin P Garcia, Daniel T O'Connor, et al.
Journal of Human Hypertension|August 31, 2007
Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to actionG Bakris, M Hill, G Mancia, et al.
Kidney International|November 12, 2020
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trialBettina J Kraus, Matthew R Weir, George L Bakris, et al.
Diabetes, Obesity & Metabolism|February 1, 2023
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baselineJanet B McGill, Rajiv Agarwal, Stefan D Anker, et al.
Diabetes Care|August 16, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 18, 2023
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney diseasePeter Rossing, Florian M M Baeres, George Bakris, et al.
American Journal of Nephrology|January 17, 2015
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathyLuis M Ruilope, Rajiv Agarwal, Juliana C Chan, et al.
The American Journal of Medicine|May 26, 2012
Awareness of kidney disease and relationship to end-stage renal disease and mortalityAdam Whaley-Connell, Michael G Shlipak, Lesley A Inker, et al.
Pageof 74

Showing results (621-630 of 738) with videos related to

Sort By:
Pageof 74
Kidney International|December 23, 2011
Renal outcomes in hypertensive Black patients at high cardiovascular riskMatthew R Weir, George L Bakris, Michael A Weber, et al.
The New England Journal of Medicine|September 3, 2013
Alogliptin after acute coronary syndrome in patients with type 2 diabetesWilliam B White, Christopher P Cannon, Simon R Heller, et al.
American Journal of Nephrology|November 13, 2009
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal diseaseVibha Bhatnagar, Erin P Garcia, Daniel T O'Connor, et al.
Journal of Human Hypertension|August 31, 2007
Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to actionG Bakris, M Hill, G Mancia, et al.
Kidney International|November 12, 2020
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trialBettina J Kraus, Matthew R Weir, George L Bakris, et al.
Diabetes, Obesity & Metabolism|February 1, 2023
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baselineJanet B McGill, Rajiv Agarwal, Stefan D Anker, et al.
Diabetes Care|August 16, 2022
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY AnalysisPeter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 18, 2023
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney diseasePeter Rossing, Florian M M Baeres, George Bakris, et al.
American Journal of Nephrology|January 17, 2015
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathyLuis M Ruilope, Rajiv Agarwal, Juliana C Chan, et al.
The American Journal of Medicine|May 26, 2012
Awareness of kidney disease and relationship to end-stage renal disease and mortalityAdam Whaley-Connell, Michael G Shlipak, Lesley A Inker, et al.
Pageof 74